ACT-334441 + diltiazem

ACT-334441 + diltiazem is a hypothetical or research-stage combination drug that consists of **ACT-334441** (the code name for selexipag, a selective prostacyclin IP receptor agonist developed for pulmonary arterial hypertension) and **diltiazem** (a non-dihydropyridine calcium channel blocker used to treat hypertension, angina, and certain cardiac arrhythmias). - **ACT-334441** (selexipag) acts by selectively activating the prostacyclin IP receptor, resulting in vasodilation and inhibition of smooth muscle cell proliferation. - **Diltiazem** inhibits the influx of calcium ions into cardiac and vascular smooth muscle, reducing heart rate, cardiac contractility, and blood pressure. The combination could theoretically provide synergistic vasodilatory and anti-proliferative effects, primarily in the management of pulmonary arterial hypertension or other cardiovascular conditions, though no such combination product is marketed or formally approved as of the latest evidence. - Diltiazem is an approved antihypertensive, anti-anginal, and anti-arrhythmic agent[1]. - This combination does not have widespread clinical trial data or regulatory approval as a fixed combination.

Brand names

CardizemCartiaMatzimTiadyltTiazac

Other names

diltiazem